| Patients treated 2000-2005 | Patients treated 2009-2012 | All patients | Statins users | Metformin users | Statins and Metformin users |
Number of patients | 302 | 79 | 381 | 146 | 27 | 12 |
Age [years] | 74.3 ± 5.6 | 74.9 ± 7 | 74.4 ± 6.0 | 74.4 ± 6.0 | 72.2 ± 6.9 | 71.0 ± 8.3 |
Follow up time (median) [months] | 91 [6 - 138] | 26 [3 - 54] | 70 [3 - 138] | 69.8 [3 - 136] | 62 [3 - 129] | 45 [3 - 128] |
Prostate Volume (mean) [cc] | 78.9 ± 32.0 | 75.3 ± 26.6 | 78.0 ± 30.7 | 78.0 ± 30.8 | 91.4 ± 32 | 77.0 ± 14 |
Baseline PSA (mean) | 9.1 ± 8.0 | 8.6 ± 6.7 | 9.0 ± 7.0 | 7.0 ± 4.8 | 5.4 ± 2.1 | 5.3 ± 1.6 |
Baseline PSA (median) | 7.0 | 6.7 | 6.8 | 6.1 | 5.3 | 5.2 |
Diabetes | 11% (N = 33) | 14% (N = 14) | 11.7% (N = 47) | 13% (N = 19) | 100% (N = 27) | 100% (N = 12) |
Hormonal Therapy [%] | 35% (N = 107) | 42% (N = 46) | 40% (N = 153) | 33% (N = 98) | 32% (N = 9) | 8.3% (N = 1) |
Gleason > 6 [%] | 56% (N = 169) | 67% (N = 53) | 58% (N = 222) | 56% (N = 82) | 37% (N = 10) | 67% (N = 8) |
Gleason = 8 - 10 [%] | 17.9% (N = 54) | 16.5% (N = 13) | 18% (N = 67) | 16% (N = 23) | 15% (N = 4) | 0% (N = 0) |
T stage > T2a [%] | 25.8% (N = 78) | 43% (N = 34) | 29% (N = 112) | 27% (N = 39) | 18.5% (N = 5) | 0% (N = 0) |
Biochemical Failure | 19.7% (N = 59) | 7.6% (N = 6) | 17% (N = 65) | 14% (N = 20) | 15.4% (N = 4) | 0% (N = 0) |
Local Failure | 3.3% (N = 10) | 2.5% (N = 2) | 3% (N = 12) | 3.5% (N = 5) | 3.7% (N = 1) | 0% (N = 0) |
Distant Failure | 5.7% (N = 17) | 5.1% (N = 4) | 5.5% (N = 21) | 3.5% (N = 5) | 3.7% (N = 1) | 0% (N = 0) |
Died of Prostate Cancer | 4.3% (N = 13) | 1% (N = 1) | 3.5% (N = 14) | 2.7% (N = 4) | 0% (N = 0) | 0% (N = 0) |
Died of Any Cause | 24% (N = 72) | 7.5% (N = 6) | 21% (N = 79) | 16% (N = 24) | 19% (N = 5) | 8% (N = 1) |
Treatment Technique | 5 field IMRT | 7 field IMRT |
|
|
|
|
Dose Prescription | Median Dose 75.6Gy in 1.8 Gy fractions | Median dose 80.3 Gy in 1.8 Gy fractions |
|
|
|
|